GREM1 antibody (C-Term)

Catalog No. ABIN966222

Product Details anti-GREM1 Antibody

Target: GREM1 (Gremlin 1 (GREM1))

Binding Specificity: C-Term

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This GREM1 antibody is un-conjugated

Application: Western Blotting (WB)

Cross-Reactivity: Mouse (Murine), Rat (Rattus)

Cross-Reactivity (Details): No cross reactivity with other proteins.

Characteristics: Rabbit IgG polyclonal antibody for Gremlin-1 (GREM1) detection. Tested with WB in Human, Mouse, Rat.

Immunogen: A synthetic peptide corresponding to a sequence at the C-terminal of human Gremlin 1, identical to the related rat and mouse sequences.< br/>Immunogen was affinity purified.

Isotype: IgG

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 µg/mL.

Buffer: Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Thimerosal, 0.05 mg Sodium azide.

Preservative: Sodium azide, Thimerosal (Merthiolate)

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: At -20 °C for one year. After reconstitution, at 4 °C for one month. It can also be aliquotted and stored frozen at -20 °C for a longer time.

References for anti-GREM1 antibody (ABIN966222)

Stabile, Mitola, Moroni, Belleri, Nicoli, Coltrini, Peri, Pessi, Orsatti, Talamo, Castronovo, Waltregny, Cotelli, Ribatti, Presta: "Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor." in: Blood, Vol. 109, Issue 5, pp. 1834-40, (2007) (PubMed).

Namkoong, Shin, Kim, Ha, Cho, Hur, Kim, Kim: "The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein." in: BMC cancer, Vol. 6, pp. 74, (2006) (PubMed).

Sox: "Office-based testing for fecal occult blood: do only in case of emergency." in: Annals of internal medicine, Vol. 142, Issue 2, pp. 146-8, (2005) (PubMed).

Gazzerro, Pereira, Jorgetti, Olson, Economides, Canalis: "Skeletal overexpression of gremlin impairs bone formation and causes osteopenia." in: Endocrinology, Vol. 146, Issue 2, pp. 655-65, (2005) (PubMed).

Target Details for GREM1

Target: GREM1 (Gremlin 1 (GREM1))

Alternative Name: Gremlin-1 (GREM1 Products)

Synonyms: grem1 antibody, MGC136702 antibody, zgc:136702 antibody, GREM1 antibody, drm antibody, pig2 antibody, dand2 antibody, ihg-2 antibody, gremlin antibody, Cktsf1b1 antibody, Drm antibody, Grem antibody, ld antibody, gremlin-1 antibody, CKTSF1B1 antibody, DAND2 antibody, DRM antibody, GREMLIN antibody, IHG-2 antibody, cktsf1b1 antibody, gremlin 1a, DAN family BMP antagonist antibody, gremlin 1, DAN family BMP antagonist antibody, gremlin 1 antibody, gremlin 1, DAN family BMP antagonist L homeolog antibody, grem1a antibody, GREM1 antibody, LOC662541 antibody, grem1 antibody, Grem1 antibody, grem1.L antibody

Background: Gremlin, also known as Drm, is a highly conserved 20. 7-kDa, 184 amino acid glycoprotein part of the DAN family and is a cysteine knot-secreted protein. Skeletal cells synthesize bone morphogenetic proteins (BMPs) and BMP antagonists. And Gremlin is expressed in osteoblasts and opposes BMP effects on osteoblastic differentiation and function in vitro. Gremlin 1 (GREM 1) is known for its antagonistic reaction with BMPs in the TGF beta signaling pathway. This gene inhibits BMP-2, BMP-4, and BMP-7. Inhibition by grem 1 of BMPs in mice allow the expression of fibroblast growth factors (FGFs) 4 and 8 and Sonic hedgehog (SHH) which are necessary for proper limb development. Gremlin 1 may play an oncogenic role especially in carcinomas of the uterine cervix, lung, ovary, kidney, breast, colon, pancreas, and sarcoma. Over-expressed gremlin 1 functions by interaction with YWHAH (Its binding site for gremlin 1 was located between residues 61-80 and gremlin 1 binding site for YWHAH was found to be located between residues 1-67). Therefore, Gremlin 1 and its binding protein YWHAH could be good targets for developing diagnostic and therapeutic strategies against human cancers.

Pathways: Regulation of Muscle Cell Differentiation, Tube Formation, Maintenance of Protein Location